1. Home
  2. LPTX vs VS Comparison

LPTX vs VS Comparison

Compare LPTX & VS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • VS
  • Stock Information
  • Founded
  • LPTX 2011
  • VS 2013
  • Country
  • LPTX United States
  • VS United States
  • Employees
  • LPTX N/A
  • VS N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • VS EDP Services
  • Sector
  • LPTX Health Care
  • VS Technology
  • Exchange
  • LPTX Nasdaq
  • VS Nasdaq
  • Market Cap
  • LPTX 11.1M
  • VS 9.6M
  • IPO Year
  • LPTX N/A
  • VS N/A
  • Fundamental
  • Price
  • LPTX $0.29
  • VS $1.97
  • Analyst Decision
  • LPTX Hold
  • VS Hold
  • Analyst Count
  • LPTX 1
  • VS 1
  • Target Price
  • LPTX N/A
  • VS $2.00
  • AVG Volume (30 Days)
  • LPTX 2.0M
  • VS 315.8K
  • Earning Date
  • LPTX 08-14-2025
  • VS 08-14-2025
  • Dividend Yield
  • LPTX N/A
  • VS N/A
  • EPS Growth
  • LPTX N/A
  • VS N/A
  • EPS
  • LPTX N/A
  • VS N/A
  • Revenue
  • LPTX N/A
  • VS $2,183,196.00
  • Revenue This Year
  • LPTX N/A
  • VS $3,459.21
  • Revenue Next Year
  • LPTX N/A
  • VS N/A
  • P/E Ratio
  • LPTX N/A
  • VS N/A
  • Revenue Growth
  • LPTX N/A
  • VS 1873.85
  • 52 Week Low
  • LPTX $0.22
  • VS $1.00
  • 52 Week High
  • LPTX $4.79
  • VS $9.59
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 46.11
  • VS 40.40
  • Support Level
  • LPTX $0.28
  • VS $1.80
  • Resistance Level
  • LPTX $0.31
  • VS $2.02
  • Average True Range (ATR)
  • LPTX 0.04
  • VS 0.19
  • MACD
  • LPTX 0.00
  • VS -0.01
  • Stochastic Oscillator
  • LPTX 39.39
  • VS 23.16

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

About VS Versus Systems Inc.

Versus Systems Inc offers a suite of proprietary business-to-business software tools that are meant to drive user engagement through gamification and rewards. These tools allow its partners to offer in-game prizes and rewards, including merchandise, coupons, digital goods, and sweepstakes entries - inside their websites, their venues, or their streaming media content. Its customers are mostly sports teams, venues, and advertising agencies, which typically use its products as part of their live events or as part of an advertising campaign with the goal of engaging fans, increasing consented first-party data, and increasing sales. The company operates in Canada and the USA.

Share on Social Networks: